KD2503

KD2503 is a small molecule candidate being developed by Kyungdong Pharmaceutical for the treatment of dry eye syndrome. It is classified by the developer as an "improved new drug" (개량신약), a regulatory category in South Korea for drugs that offer improvements in safety, efficacy, or usefulness over existing products through modifications in formulation, salt, or delivery. As of late 2025, the program is in the discovery stage. While specific molecular targets have not been disclosed, the drug is intended to address the underlying pathology or symptoms of dry eye syndrome, potentially through enhanced ocular bioavailability or reduced dosing frequency compared to current standards of care.